Enjaymo
| Chemical Name | sutimlimab-jome |
| Dosage Form | Injection (intravenous; 1,100 mg/22 mL (50 mg/mL)) |
| Drug Class | Inhibitors |
| System | Blood |
| Company | Bioverativ |
| Approval Year | 2022 |
Indication
- Indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)